Insmed Incorporated (NASDAQ:INSM) Shares Bought by Blue Trust Inc.

Blue Trust Inc. raised its holdings in Insmed Incorporated (NASDAQ:INSM) by 2,348.8% during the third quarter, HoldingsChannel reports. The firm owned 1,959 shares of the biopharmaceutical company’s stock after buying an additional 1,879 shares during the period. Blue Trust Inc.’s holdings in Insmed were worth $131,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of INSM. V Square Quantitative Management LLC acquired a new position in shares of Insmed during the third quarter worth about $30,000. Creative Planning increased its stake in shares of Insmed by 31.2% during the third quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company’s stock worth $3,279,000 after acquiring an additional 10,668 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the period. Tobam acquired a new position in shares of Insmed during the third quarter worth about $464,000. Finally, Atomi Financial Group Inc. increased its stake in shares of Insmed by 1.4% during the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock worth $1,697,000 after acquiring an additional 314 shares during the period.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the transaction, the insider now owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,882 shares of company stock valued at $5,765,446. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

INSM has been the topic of a number of recent analyst reports. Truist Financial boosted their price target on shares of Insmed from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, October 11th. TD Cowen boosted their price target on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com lowered shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $82.73.

Insmed Stock Performance

Shares of INSM opened at $70.96 on Monday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The company has a market capitalization of $10.55 billion, a price-to-earnings ratio of -13.57 and a beta of 1.11. The company’s 50 day simple moving average is $73.83 and its 200 day simple moving average is $60.03. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same period last year, the business earned ($1.78) earnings per share. The business’s revenue was up 17.0% compared to the same quarter last year. On average, sell-side analysts predict that Insmed Incorporated will post -5.41 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.